ImmunoGen slumps, despite positive SORAYA trial of mirvetuximab

21 March 2022

US antibody-drug conjugate (ADC) specialist ImmunoGen (Nasdaq: IMGN) has announced full results from the pivotal SORAYA trial evaluating the efficacy and safety of mirvetuximab soravtansine (mirvetuximab: IMGN853) monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).

The trial met its primary endpoint, with confirmed objective rates of 32.45, including five complete responses, and the company expects to submit a Biologic License Application (BLA) with the US Food and Drug Administration this month. Despite the positive news, ImmunoGen’s shares were down more than 25% at $3.93 in early trading this morning.

The results are being presented by Dr Ursula Matulonis in the late-breaking abstract plenary session on Saturday, March 19, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting in Phoenix, AZ.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK